Amgen (AMGN) Price Target Lifted to $187 at Leerink Partners
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Nasdaq notches record high close as investors focus on earnings
- Oil slips on rising Mideast crude exports, G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
- Five things to watch in markets in the week ahead
- Citi cuts investment banking analyst program to two years - Bloomberg
- Alaska LNG shipping savings justifies billions in investment, developer says
- Paramount Skydance to close WBD deal, change ticker to SKYD
- Nasdaq notches record high close as investors focus on earnings
- Oil slips on rising Mideast crude exports, G7 stocks release
Amgen (AMGN) Price Target Raised to $195 at Jefferies
April 22, 2015 11:41 AM EDTIn a note earlier, Jefferies analyst Eun K. Yang reiterated a Buy rating and boosted his price target on Amgen (NASDAQ: AMGN) to $195.00 (from $182.00) following Q1 results.
Yang commented, "Reported ~18% higher EPS (vs. cons) on ~3% higher product sales & lower OpEx; upped FY15 EPS guidance... More
Amgen (AMGN) Tops Q1 EPS by 38c; Boosts FY15 Outlook
April 21, 2015 4:03 PM EDTAmgen (NASDAQ: AMGN) reported Q1 EPS of $2.48, $0.38 better than the analyst estimate of $2.10. Revenue for the quarter came in at $5.03 billion versus the consensus estimate of $4.91 billion.
Amgen sees FY2015 EPS of $9.35 - $9.65, versus the consensus of $9.32. Amgen sees FY2015 revenue of $20.9 - $21.3... More



